Graphite Bio agrees repairing autologous hematopoietic stem cells (HSCs) through CRISPR is difficult. But the company claims its targeted gene integration platform and manufacturing technologies considerably upgrade the original CRISPR/Cas9 approach. Improved targeting can lead to higher rates of homology directed repair (HDR) in genes, which assures efficient incorporation of repaired genes into the genome, according to the company. SanaCurrents assigns a speculative rating Graphite will report positive initial proof-of-concept data from its phase I/II trial results testing its lead drug GPH101 in SCD.